5,6-二氯-3-吡啶甲醇 | 54127-30-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5,6-二氯-3-吡啶甲醇
• 中文别名: 2,3-二氯-5-羟基甲基嘧啶；5,6-二氯吡啶-3-甲醇；5,6-二氯-3-嘧啶甲醇
• 英文名称: 5,6-dichloro-3-pyridinemethanol
• 英文别名: (5,6-dichloropyridin-3-yl)methanol；(5,6-dichloro-3-pyridyl)methanol；2,3-dichloro-5-(hydroxymethyl)-pyridine
• CAS: 54127-30-9
• 化学式: C₆H₅Cl₂NO
• mdl: MFCD00671515
• 分子量: 178.018
• InChiKey: ZOFUUOULXZPZHP-UHFFFAOYSA-N

物化性质

• 熔点：
  76°C
• 沸点：
  297.7±35.0 °C(Predicted)
• 密度：
  1.478
• 稳定性/保质期：
  如果按照规定使用和储存，则不会分解，未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险类别码：
  R36/37/38
• 安全说明：
  S26,S36,S37,S39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将贮藏器密封保存，并将其存放在阴凉、干燥的地方。同时，确保工作环境有良好的通风或排气设施。

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name 5,6-Dichloro-3-pyridinemethanol
Portland OR
3-Pyridinemethanol, 5,6-dichloro- (9CI)
Synonym
C6H5Cl2NO
Chemical Formula
CAS Number 54127-30-9

---

Section II. Composition and Information on Ingredients
Chemical Name CAS Number Percent (%) TLV/PEL Toxicology Data
5,6-Dichloro-3-pyridinemethanol 54127-30-9 Min. 96.0 Not available. Not available.
(GC)

---

Section III. Hazards Identification
Acute Health Effects No specific information is available in our data base regarding the toxic effects of this material for humans. However,
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling
this compound.
CARCINOGENIC EFFECTS : Not available.
Chronic Health Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

---

Section IV. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
Inhalation
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
Ingestion INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the
toxic material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Not available.
Auto-Ignition
Flammability May be combustible at high temperature.
Flash Points Flammable Limits Not available.
Not available.
Combustion Products These products are toxic carbon oxides (CO, CO2), nitrogen oxides (NO, NO2), halogenated compounds.
WARNING: Highly toxic HCl gas is produced during combustion.
Fire Hazards
Not available.
Explosion Hazards Risks of explosion of the product in presence of mechanical impact: Not available.
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
5,6-Dichloro-3-pyridinemethanol

---

Section VI. Accidental Release Measures
Spill Cleanup Use a shovel to put the material into a convenient waste disposal container. Finish cleaning the spill by rinsing any
contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on
Instructions
disposal.

---

Section VII. Handling and Storage
Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container and store in a dry, cool
Handling and Storage
place. Avoid excessive heat and light. Do not breathe dust.
Information
Always store away from incompatible compounds such as oxidizing agents.

---

Section VIII. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Splash goggles. Lab coat. Dust respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult
a specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Exposure Limits Not available.

---

Section IX. Physical and Chemical Properties
Solid. (Light Yellow Powder.) Solubility
Physical state @ 20°C Not available.
Not available.
Specific Gravity
Molecular Weight 178.02 Partition Coefficient Not available.
Boiling Point
Not available. Vapor Pressure Not applicable.
Melting Point 76°C (168.8°F) Vapor Density Not available.
Refractive Index Not available. Volatility Not available.
Critical Temperature Not available. Odor Not available.
Viscosity Not available. Taste Not available.

---

Section X. Stability and Reactivity Data
Stability

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Conditions of Instability Avoid excessive heat and light.
Incompatibilities Reactive with oxidizing agents.

---

Section XI. Toxicological Information
Not available.
RTECS Number
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Toxicity Data Not available.
Chronic Toxic Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Acute Toxic Effects No specific information is available in our data base regarding the toxic effects of this material for humans. However,
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling
this compound.
Continued on Next Page
5,6-Dichloro-3-pyridinemethanol

---

Section XII. Ecological Information
Ecotoxicity Not available.
Not available.
Environmental Fate

---

Section XIII. Disposal Considerations
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
Waste Disposal
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
DOT Classification Not a DOT controlled material (United States).
Not applicable.
PIN Number
Proper Shipping Name
Not applicable.
Packing Group (PG) Not applicable.
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification Not available.
(Canada)
EINECS Number (EEC) Not available.
EEC Risk Statements Not available.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

5,6-二氯-3-吡啶甲醇是一种新型CXCR3（CXC趋化因子受体）抑制剂，并且也被用于合成吡啶基组蛋白去乙酰化酶抑制剂。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  5,6-二氯烟酸	5,6-dichloronicotinic acid	41667-95-2	C6H3Cl2NO2	192.001
  5,6-二氯烟酸甲酯	methyl 2,3-dichloro-pyridine-5-carboxylate	56055-54-0	C7H5Cl2NO2	206.028
  2,3-二氯-5-甲酰基吡啶	5,6-dichloro-pyridine-3-carbaldehyde	71690-05-6	C6H3Cl2NO	176.002
  3-氨基-4-羟基吡啶盐酸盐	ethyl 5,6-dichloronicotinate	401566-69-6	C8H7Cl2NO2	220.055
  2,3-二氯吡啶-5-羰酰氯	5,6-dichloronicotinoyl chloride	54127-29-6	C6H2Cl3NO	210.447

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  2,3-二氯-5-(甲氧基甲基)吡啶	2,3-dichloro-5-(methoxymethyl)pyridine	202395-72-0	C7H7Cl2NO	192.045
  ——	1-(5,6-dichloropyridin-3-yl)ethan-1-ol	683243-82-5	C7H7Cl2NO	192.045
  ——	(5,6-dichloropyridin-3-yl)methyl methanesulfonate	1073618-07-1	C7H7Cl2NO3S	256.109
  ——	(R)-1-(5,6-dichloropyridin-3-yl)ethane-1,2-diol	1073617-84-1	C7H7Cl2NO2	208.044
  ——	(S)-1-(5,6-dichloropyridin-3-yl)ethane-1,2-diol	1073617-83-0	C7H7Cl2NO2	208.044
  2,3-二氯-5-甲酰基吡啶	5,6-dichloro-pyridine-3-carbaldehyde	71690-05-6	C6H3Cl2NO	176.002
  2,3-二氯-5-(溴甲基)吡啶	2,3-Dichloro-5-(bromomethyl)pyridine	287714-93-6	C6H4BrCl2N	240.914
  1-(5,6-二氯-3-吡啶基)甲胺	(5,6-dichloro-3-pyridyl)methanamine	1256794-26-9	C6H6Cl2N2	177.033
  2,3-二氯-5-(氯甲基)吡啶	5-chloromethyl-2,3-dichloropyridine	54127-31-0	C6H4Cl3N	196.463
  2,3-二氯-5-乙烯基吡啶	2,3-dichloro-5-vinylpyridine	1001193-62-9	C7H5Cl2N	174.029

反应信息

• 作为反应物：
  描述：

  5,6-二氯-3-吡啶甲醇 在 manganese(IV) oxide 、 AD-mix-β 、 potassium osmate 、 双(三甲基硅烷基)氨基钾 、 potassium carbonate 、 potassium hexacyanoferrate(III) 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 甲苯 、 叔丁醇 为溶剂， 反应 75.5h， 生成 (R)-1-(5,6-dichloropyridin-3-yl)ethane-1,2-diol
  参考文献：
  名称：

  WO2008/132600

  摘要：

  公开号：
• 作为产物：
  描述：

  5,6-二氯烟酸 在 硼烷四氢呋喃络合物 、 水 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 以61%的产率得到5,6-二氯-3-吡啶甲醇
  参考文献：
  名称：

  BICYCLIC ENAMINO(THIO)CARBONYL COMPOUNDS

  摘要：

  本发明涉及新颖的双环烯胺基(硫)酰基化合物，以及其制备方法和用于控制动物害虫，特别是节肢动物，尤其是昆虫的用途。

  公开号：

  US20090181947A1

文献信息

• Vanilloid receptor ligands and their use in treatments
  申请人：Gore Keshav Vijay

  公开号：US20060084640A1

  公开（公告）日：2006-04-20

  Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  治疗性苯并咪唑及含有它们的组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合征、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症症状、炎症性疼痛及相关的过敏性疼痛和触痛、神经痛及相关的过敏性疼痛和触痛、糖尿病性神经病痛、烧灼性疼痛、交感神经维持性疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、消化或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃病变、毛发生长、血管运动性或过敏性鼻炎、支气管疾病或膀胱疾病。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV WAYNE STATE

  公开号：WO2011079305A1

  公开（公告）日：2011-06-30

  The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I.

  该发明提供了如下所述的式I化合物或其盐。该发明还提供了包括式I化合物的药物组合物，制备式I化合物的方法，用于制备式I化合物的有用中间体以及利用式I化合物诱导凋亡或治疗癌症的治疗方法。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。
• Sulfonamides
  申请人：Galley Guido

  公开号：US20060014945A1

  公开（公告）日：2006-01-19

  The invention relates to compounds of the general formula in which R 1 , R 2 , R3, R 4 , R 2′ , R3′, R 4′ , R 5 , and X is —CHR— are as defined in the specification. The invention also provides pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures of such compounds. The invention further provides methods for the treatment of Alzheimer's disease or common cancers.

  该发明涉及一般式化合物，其中R1、R2、R3、R4、R2'、R3'、R4'、R5和X为规范中定义的—CHR—。该发明还提供药学上可接受的酸盐加合物，光学纯对映体，外消旋体和这类化合物的二对映异构体混合物。该发明还提供治疗阿尔茨海默病或常见癌症的方法。
• COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
  申请人：Wu Tom Yao Hsiang

  公开号：US20110053893A1

  公开（公告）日：2011-03-03

  The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

  这项发明提供了一类新型化合物，包括这类化合物的免疫原组合物和药物组合物，以及利用这类化合物治疗或预防与Toll样受体7相关的疾病或紊乱的方法。在一个方面，这些化合物可用作辅助剂，以增强疫苗的有效性。

表征谱图